Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672712 | 0.90 | ALDH1A1 (0.48) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL30672747 | 0.90 | ALDH1A1 (0.48) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL30210424 | 0.86 | PDE4B (0.49) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL18342179 | 0.85 | ALDH1A1 (0.53) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL20479723 | 0.85 | ALDH1A1 (0.53) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL19063792 | 0.85 | CTSK (0.58) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL18342411 | 0.85 | ALDH1A1 (0.53) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL4366638 | 0.85 | CTSK (0.58) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL4364990 | 0.85 | CTSK (0.58) | CPB1ALDH1A1GAACTSKCTSL | |
| SCHEMBL9993970 | 0.85 | CTSK (0.58) | CPB1ALDH1A1GAACTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4139299-A1 | KRAS G12D PROTEIN INHIBITORS | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021215544-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | KRAS, NRAS, HRAS | CPB1 3758/4885ALDH1A1 3803/4885GAA 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.